Eradication rates and adverse effects
| Outcomes | S10 | T14 | p Value |
|---|---|---|---|
| Eradication rate (%) | |||
| ITT analysis, %, N | 87.2% (567/650) | 85.7% (557/650) | 0.418 |
| 95% CI | 84.4% to 89.6% | 82.8% to 88.2% | |
| PP analysis, %, N | 91.6% (556/607) | 91.0% (548/602) | 0.726 |
| 95% CI | 89.1% to 93.4% | 88.5% to 93.1% | |
| Adverse effects (%) | |||
| Dizziness | 7.2% (46/642) | 5.3% (34/642) | 0.356 |
| Skin rash | 1.9% (12/642) | 2.5% (16/642) | 0.679 |
| Headache | 3.9% (25/642) | 4.1% (26/642) | 0.904 |
| Taste distortion | 11.7% (75/642) | 14.3% (92/642) | 0.124 |
| Abdominal pain | 5.3% (34/642) | 5.0% (32/642) | 0.403 |
| Nausea | 5.3% (34/642) | 2.8% (18/642) | 0.04 |
| Diarrhoea | 11.3% (73/642) | 14.8% (93/642) | 0.245 |
| Constipation | 1.9% (12/642) | 3.5% (22/642) | 0.116 |
| Bloating | 5.9% (38/642) | 7% (45/642) | 0.727 |
| Vomiting | 1.5% (10/642) | 2.1% (13/642) | 0.283 |
| Any adverse effects | 38.2% (245/642) | 42.2% (271/642) | 0.139 |
| Discontinued drugs due to adverse effects | 2.3% (15/642) | 2.8% (18/642) | 0.597 |
| Took at least 80% of drugs | 96.3% (626/650) | 94.6% (615/650) | 0.143 |
| Took the drugs correctly | 97.1% (631/650) | 96.6% (628/650) | 0.634 |
The taste distortion indicated any changes in the taste sensation, such as bitter sensation.
ITT, intention-to-treat; N, number; PP, per-protocol; S10, sequential therapy for 10 days; T14, triple therapy for 14 days.